Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500313 | 0.86 | CHRM4 (0.58) | CHRM4DRD2DRD3 | |
| SCHEMBL4522460 | 0.85 | GPR119 (0.55) | CHRM4HTR7 | |
| SCHEMBL3844960 | 0.84 | CHRM4 (0.50) | CHRM4POLBCCR5HTR7DRD2 | |
| SCHEMBL3487510 | 0.82 | KDM4E (0.47) | CHRM4POLB | |
| SCHEMBL1779457 | 0.80 | KDM4E (0.59) | CHRM4POLB | |
| SCHEMBL4755524 | 0.80 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL4514129 | 0.80 | DRD2 (0.58) | DRD2DRD3HTR1A | |
| SCHEMBL4701304 | 0.79 | DRD2 (0.49) | DRD2DRD3HTR1A | |
| SCHEMBL4484274 | 0.78 | DRD3 (0.60) | DRD2DRD3 | |
| SCHEMBL13630214 | 0.78 | DRD3 (0.60) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | CHRM4 522/4885POLB 4473/4885CCR5 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.